OncoRisk Panel

Introduction

No genetic cause for all types of cancer has been identified. Most cases of cancer occur in the absence of a significant family history and are not inherited. In these families, the mutations that cause the cancer occur only in the tumor itself and are acquired after birth. However, about 5-10% of cancers are considered hereditary, and several genetic changes or mutations can be passed from parent to child and increase a person's risk of developing the disease. The mutated genes are also known as "cancer susceptibility genes". Examples of hereditary cancer syndromes are hereditary breast and ovarian cancer syndrome, Li-Fraumeni syndrome, Cowden syndrome, and Lynch syndrome, etc.

We offer the hereditary cancer panel to detect genetic mutations, covering 37 genes associated with cancer. Here, CD Genomics offers an OncoRisk panel for a comprehensive analysis of oncogenes. The panel can analyze 31 oncogenes associated with inherited cancer, which are precisely selected from contract research organizations and numerous research studies.

OncoRisk Panel

APC ATM BARD1 BLM BMPR1A BRCA1 BRCA2 BRIP1 CDH1 CDK4 CDKN2A CHEK2 EPCAM MLH1 MRE11A MSH2 MSH6 MUTYH NBN PALB2 PMS2 PRSS1 PTEN RAD50 RAD51C RAD51 DSLX4 SMAD4 STK11 TP53 VHL

Our OncoRisk panel offers but not limited to:

Designed to efficiently and accurately analyze 31 inherited cancer-associated genes. Reduces total sequencing costs compared to whole genome sequencing or whole exome sequencing.
Strict quality control throughout the pipeline workflow ensures the accuracy and reproducibility of sequencing.
The panel can detect mutant types including SNV, Indel, CNV and rearrangements.
Bioinformatics results for large deletion analysis are available through a powerful bioinformatics system.
The panel is used for homologous recombination defect (HRD) detection, providing information for HRD grade calculation to aid precision medicine for oncology treatment.
The panel's high performance ensures reliable and consistent sequencing results for customers, even when using DNA from low-quality clinical samples or FFPE.
Our advanced in-house targeted enrichment platform allows you to select and customize the target capture probes according to your research requirements, ensuring that you can focus on the specific genomic regions of interest. Contact us for more details.

Features of our OncoRisk panel

Target Enrichment Method: Hybridization.

Library Preparation Options: All the necessary components for routine library preparation could be involved in our package, such as all-in-one beads/polymerase package option for convenience and efficiency.

Specimen: Blood (> 50 ng of fragmented DNA), FFPE sample.

Market-leading Sensitivity and Specificity: All types of mutations with over 95% sensitivity at 5% VAF, and 99.9% and 99.5% specificity for SNV and Indel, respectively.

Sequencing Platforms: All kinds of Sequencing devices, including Illumina, MGI, PacBio and Nanopore Sequencing platforms.

Bioinformatics Service:

Gene panel workflow

CD Genomics provides accurate and cost-effective panel sequencing and bioinformatics analysis of 31 oncogenes associated with inherited cancer. Our dedicated team of experts performs quality management, following every procedure to ensure confident and unbiased results. The general workflow for OncoRisk panel is outlined below.

OncoRisk Panel

Our OncoRisk panel data may contribute to the development of the era of personalized medicine, specific treatment for each disease-causing mutation in hereditary cancer susceptibility genes, and rational prevention strategies. We look forward to working with you on your innovative discoveries, so please do not hesitate to contact us.

Reference:

1.LaDuca H, et al. (2020) A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients[J]. Genetics in Medicine. 22(2): 407-415.

* For Research Use Only. Not for use in diagnostic procedures.